Biopharma's stock market winners of 2022 revealed
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
If at first... pharma’s most drawn-out development timelines revealed
Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.
Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Argenx takes a step towards convenience
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.